Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) CFO Mark J. Vignola sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the transaction, the chief financial officer now directly owns 91,940 shares of the company’s stock, valued at approximately $1,011,340. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Terns Pharmaceuticals Price Performance
Shares of NASDAQ TERN opened at $9.51 on Friday. Terns Pharmaceuticals, Inc. has a 1 year low of $3.26 and a 1 year high of $11.40. The firm has a 50-day moving average of $8.02 and a 200 day moving average of $6.94.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.04. On average, equities analysts forecast that Terns Pharmaceuticals, Inc. will post -1.31 EPS for the current year.
Hedge Funds Weigh In On Terns Pharmaceuticals
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on TERN shares. JMP Securities boosted their price target on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the company a “market outperform” rating in a research report on Tuesday. BMO Capital Markets reissued an “outperform” rating and issued a $19.00 target price on shares of Terns Pharmaceuticals in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Terns Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $14.50.
Get Our Latest Analysis on Terns Pharmaceuticals
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Further Reading
- Five stocks we like better than Terns Pharmaceuticals
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Fresh Stock Buybacks: These are the Ones to Buy
- 3 Healthcare Dividend Stocks to Buy
- Tesla’s New Buy Rating: Why Analysts Are Optimistic
- What Are the FAANG Stocks and Are They Good Investments?
- Is Halliburton Stock a Good Buy at Current Levels?
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.